AnaptysBio, Inc. (NASDAQ:ANAB) Short Interest Update

AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) was the recipient of a large increase in short interest in the month of February. As of February 15th, there was short interest totalling 9,310,000 shares, an increase of 54.4% from the January 31st total of 6,030,000 shares. Based on an average daily volume of 932,600 shares, the short-interest ratio is presently 10.0 days.

Insider Buying and Selling at AnaptysBio

In other news, Director Ecor1 Capital, Llc purchased 65,184 shares of the business's stock in a transaction on Monday, December 30th. The stock was purchased at an average cost of $12.92 per share, with a total value of $842,177.28. Following the acquisition, the director now directly owns 7,860,180 shares in the company, valued at approximately $101,553,525.60. This trade represents a 0.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 33.70% of the company's stock.

Hedge Funds Weigh In On AnaptysBio

A number of hedge funds have recently modified their holdings of ANAB. Tower Research Capital LLC TRC increased its position in shares of AnaptysBio by 131.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 2,697 shares of the biotechnology company's stock valued at $36,000 after acquiring an additional 1,531 shares during the period. KLP Kapitalforvaltning AS purchased a new position in shares of AnaptysBio in the fourth quarter valued at about $40,000. AlphaQuest LLC increased its position in shares of AnaptysBio by 1,891.5% in the fourth quarter. AlphaQuest LLC now owns 4,461 shares of the biotechnology company's stock valued at $59,000 after acquiring an additional 4,237 shares during the period. Virtus ETF Advisers LLC increased its position in shares of AnaptysBio by 24.7% in the fourth quarter. Virtus ETF Advisers LLC now owns 4,733 shares of the biotechnology company's stock valued at $63,000 after acquiring an additional 936 shares during the period. Finally, Russell Investments Group Ltd. boosted its stake in shares of AnaptysBio by 1,585.8% during the 4th quarter. Russell Investments Group Ltd. now owns 5,698 shares of the biotechnology company's stock valued at $75,000 after purchasing an additional 5,360 shares in the last quarter.

Remove Ads

AnaptysBio Stock Performance

NASDAQ:ANAB traded up $1.50 during trading hours on Wednesday, reaching $16.75. The company's stock had a trading volume of 687,767 shares, compared to its average volume of 1,065,418. The firm has a market capitalization of $509.69 million and a price-to-earnings ratio of -2.75. The firm has a 50-day simple moving average of $16.11 and a 200-day simple moving average of $24.27. AnaptysBio has a 1 year low of $12.21 and a 1 year high of $41.31.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.61) by $0.89. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The firm had revenue of $43.11 million for the quarter, compared to analysts' expectations of $10.17 million. Equities analysts anticipate that AnaptysBio will post -6.08 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Wedbush reissued an "outperform" rating and issued a $40.00 price target on shares of AnaptysBio in a report on Wednesday, February 12th. Guggenheim lowered their price objective on shares of AnaptysBio from $90.00 to $36.00 and set a "buy" rating on the stock in a research report on Thursday, December 12th. Truist Financial lowered their price objective on shares of AnaptysBio from $30.00 to $20.00 and set a "hold" rating on the stock in a research report on Wednesday, December 18th. BTIG Research cut shares of AnaptysBio from a "buy" rating to a "neutral" rating in a research report on Monday, December 2nd. Finally, HC Wainwright restated a "neutral" rating and set a $22.00 price objective on shares of AnaptysBio in a research report on Tuesday. Four investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $35.11.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.